CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors
2020年4月29日 - 5:05AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced the appointment of
Halley E. Gilbert to the company’s board of directors. Ms. Gilbert
brings to CytomX extensive leadership experience in the
biopharmaceutical industry, with particular expertise in corporate
and business development, legal, compliance and corporate
strategy.
"Halley brings
highly complementary strategic expertise to the CytomX Board as we
continue to build a long-term company and prosecute a broad-based
strategy towards impacting the treatment of cancer and maximizing
value creation from our novel technology platform,” said Sean
McCarthy, D.Phil., president, chief executive officer and chairman
of CytomX. “The Board and I look forward to drawing upon Halley’s
extensive operational insights at this exciting time for
CytomX.”
Ms. Gilbert
brings to CytomX 20 years of operational, transactional, and
strategic leadership experience within the biopharmaceutical sector
in roles overseeing the transformation of companies from
development to commercial stage. Ms. Gilbert most recently
served as senior vice president, corporate development and chief
administrative officer of Ironwood Pharmaceuticals, Inc. where she
oversaw corporate and business development, legal, compliance and
government affairs. Prior to joining Ironwood, Ms. Gilbert served
as vice president, deputy general counsel at Cubist
Pharmaceuticals, Inc. (acquired by Merck), where she managed the
legal function during the company’s first commercial launch of an
acute care antibiotic. Prior to this Ms. Gilbert served as
corporate counsel at Genzyme Corporation (acquired by Sanofi). Ms.
Gilbert began her career at the law firm of Skadden, Arps, Slate,
Meagher & Flom LLP, where she specialized in mergers and
acquisitions and securities law. Ms. Gilbert currently serves on
the board of Arcutis Biotherapeutics, and formerly served on the
boards of Dermira, Inc. (acquired by Eli Lilly and Company) and
Achaogen, Inc. Ms. Gilbert received a J.D. from Northwestern
University School of Law and a B.A. from Tufts
University.
“I am delighted
to be joining the CytomX board and look forward to contributing to
the company’s mission of changing the treatment of cancer with the
advancement of the Probody platform and clinical pipeline,” said
Ms. Gilbert.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused
biopharmaceutical company with a vision of transforming lives with
safer, more effective therapies. We are developing a novel class of
investigational antibody therapeutics, based on our
Probody® technology platform, for the treatment of cancer.
Probody therapeutics are designed to remain
inactive until they are activated by proteases in the tumor
microenvironment. As a result, Probody therapeutics are intended to
bind selectively to tumors and decrease binding to healthy tissue,
to minimize toxicity and potentially create safer, more effective
therapies. As leaders in the field, our innovative technology is
designed to turn previously undruggable targets into druggable
targets and to enable more effective combination therapies. CytomX
and its partners, comprised of leading biotechnology and
pharmaceutical companies, have developed a robust pipeline of
potential first-in-class therapeutic candidates against novel,
difficult to drug targets and potential best-in-class
immunotherapeutic candidates against clinically validated targets.
The CytomX clinical stage pipeline includes first-in-class product
candidates against previously undruggable targets, including a
CD166-targeting Probody drug conjugate wholly owned by CytomX
(CX-2009) and a CD71-targeting Probody drug conjugate partnered
with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that
are considered to be inaccessible to conventional antibody drug
conjugates due to their presence on many healthy tissues. The
CytomX clinical stage pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb. CytomX has strategic drug
discovery and development collaborations with AbbVie, Amgen,
Astellas and Bristol Myers Squibb. For additional information
about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking
Statements
This press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements, including
those relating to the potential benefits, safety and efficacy of
CytomX’s or any of its collaborative partners’ product candidates,
administered separately or in combination, the potential benefits
or applications of CytomX’s Probody platform technology, CytomX’s
ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing and
planned clinical trials of CX-2009 and CX-2029. Risks and
uncertainties that contribute to the uncertain nature of the
forward-looking statements include: the unproven nature of CytomX’s
novel Probody Platform technology; CytomX’s clinical trial product
candidates are in the initial stages of clinical development and
its other product candidates are currently in preclinical
development, and the process by which preclinical and clinical
development could potentially lead to an approved product is long
and subject to significant risks and uncertainties, including the
risk that the COVID-19 worldwide pandemic may continue to
negatively impact the development of preclinical and clinical drug
candidates, including delaying or disrupting the enrollment of
patients in clinical trials; the possibility that the results of
early clinical trials may not be predictive of future results; the
possibility that CytomX’s clinical trials will not be successful;
the possibility that current pre-clinical research may not result
in additional product candidates; CytomX’s dependence on the
success of CX-2009, CX-2029, BMS-986249 and BMS-986288; CytomX’s
reliance on third parties for the manufacture of the company’s
product candidates; and possible regulatory developments
in the United States and foreign countries.
Additional applicable risks and uncertainties include those
relating to our preclinical research and development, clinical
development, and other risks identified under the heading "Risk
Factors" included in CytomX’s Annual Report on Form 10-K filed with
the SEC on February 27, 2020. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Probody is a U.S. registered trademark
of CytomX Therapeutics, Inc.
Investors and Media Contact:
Christopher Keenan VP, Investor Relations and
Corporate Communications ckeenan@cytomx.com
650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024